Johnson & Johnson STELARA — Percent Change (as a percent) decreased by 3216.7% to -59.7% in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 77.2%, from -33.7% to -59.7%. Over 2 years (FY 2023 to FY 2025), STELARA — Percent Change (as a percent) shows a downward trend with a 91.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Positive growth indicates expanding market share or increased utilization, whereas negative growth suggests potential market saturation, loss of exclusivity, or competitive displacement.
This metric measures the period-over-period growth rate of net sales for a specific pharmaceutical product. It provides...
Comparable to year-over-year or quarter-over-quarter revenue growth rates for specific product lines or therapeutic areas reported by peer pharmaceutical firms.
jnj_segment_stelara_percent_change_as_a_percent| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | 34% | 22.2% | 6.5% | 14.3% | 3% | 6.8% | 7.6% | 16.9% | 1.2% | 0.3% | 3.1% | -6.6% | -3.4% | -33.7% | -42.7% | -41.3% | -1.8% | -59.7% |
| QoQ Change | — | -34.7% | -70.7% | +120.0% | -79.0% | +126.7% | +11.8% | +122.4% | -92.9% | -75.0% | +933.3% | -312.9% | +48.5% | -891.2% | -26.7% | +3.3% | +95.6% | <-999% |
| YoY Change | — | — | — | -57.9% | -86.5% | +4.6% | -46.9% | +463.3% | — | -95.6% | -59.2% | -139.1% | -383.3% | <-999% | <-999% | -525.8% | +47.1% | -77.2% |